Trial reportThe Journal of allergy and clinical immunology2024
Activated sputum eosinophils associated with exacerbations in children on mepolizumab.
Trial report in The Journal of allergy and clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review.Frontiers in medicine · 2026Pooled it
- Eosinophil biology in COPD: from scientific insight to clinical treatment action.ERJ open research · 2026Review
- Review
- Paucigranulocytic Asthma in Aspirin-Hypersensitive Patients: Pleiotropic Regulation of Type 2 Biomarkers.Clinical and translational allergy · 2026Article
- Emerging Targeted Therapies in Asthma: From Upstream Epithelial Biology to Novel Biologic and Small-Molecule Strategies.Tuberculosis and respiratory diseases · 2026Review
- Review
- Biological treatments for asthma and chronic obstructive pulmonary disease.BMJ medicine · 2026Review
- Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection.Frontiers in allergy · 2026Review
- Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Review of Efficacy, Safety, and Clinical Applications.Journal of inflammation research · 2026Review
- Predictors of asthma exacerbation between high and low blood eosinophil counts.ERJ open research · 2025Article
- Airway Immune Signatures in Severe and Fatal Infection with COVID-19.American journal of respiratory cell and molecular biology · 2025Article
- Parasympathetic Airway Hyperreactivity Is Enhanced in Acute but Not Chronic Eosinophilic Asthma Mouse Models.American journal of respiratory cell and molecular biology · 2025Article
- Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group.Children (Basel, Switzerland) · 2025Review
- Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma.Frontiers in immunology · 2025Article
- Evaluating Severe Therapy-Resistant Asthma in Children: Diagnostic and Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Does Eosinophil Heterogeneity Translate into Functional Diversity? A Review of the Evolving Paradigm of Eosinophil Heterogeneity in Asthma.Biomedicines · 2024Review
- Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature.Children (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 11 institutions in 1 country.
Funding
Abstract
backgroundMUPPITS-2 was a randomized, placebo-controlled clinical trial that demonstrated mepolizumab (anti-IL-5) reduced exacerbations and blood and airway eosinophils in urban children with severe eosinophilic asthma. Despite this reduction in eosinophilia, exacerbation risk persisted in certain patients treated with mepolizumab. This raises the possibility that subpopulations of airway eosinophils exist that contribute to breakthrough exacerbations.
objectiveWe aimed to determine the effect of mepolizumab on airway eosinophils in childhood asthma.
methodsSputum samples were obtained from 53 MUPPITS-2 participants. Airway eosinophils were characterized using mass cytometry and grouped into subpopulations using unsupervised clustering analyses of 38 surface and intracellular markers. Differences in frequency and immunophenotype of sputum eosinophil subpopulations were assessed based on treatment arm and frequency of exacerbations.
resultsMedian sputum eosinophils were significantly lower among participants treated with mepolizumab compared with placebo (58% lower, 0.35% difference [95% CI 0.01, 0.74], P = .04). Clustering analysis identified 3 subpopulations of sputum eosinophils with varied expression of CD62L. CD62L
conclusionsChildren with eosinophilic asthma treated with mepolizumab had significantly lower sputum eosinophils. However, CD62L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.